{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-024358","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.735670+00:00","generated_at":"2026-06-06T01:27:25.523652+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B","bullets":["FY23 revenue $6.3B (+1% as-reported, +3% constant currency).","FY23 diluted EPS $3.99, non-GAAP adjusted diluted EPS $4.14; Adj. EBITDA $1.9B (31% margin).","Q4 revenue $1.60B (+8% YoY); Q4 non-GAAP adj. diluted EPS $0.88 (+9%).","Biosimilars rev +49% (Hadlima >doubled); Women's Health +7% (Follistim +63% ex-FX).","FY2024 guidance: revenue $6.2-6.5B, Adj. EBITDA margin 31-33%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-024358","json":"https://secwatch.observer/filing/0001104659-24-024358.json","markdown":"https://secwatch.observer/filing/0001104659-24-024358.md","text":"https://secwatch.observer/filing/0001104659-24-024358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/0001104659-24-024358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/tm246328d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:27:25.523652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f06ced1a99972f10b23bfefb83d2f822878f94","claim":"Organon & Co. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 15, 2024, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/0001104659-24-024358-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}